Trial Profile

Post injection syndrome in patients with schizophrenia receiving Olanzapine Long Acting Injection.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olanzapine (Primary)
Indications Schizophrenia
Focus Adverse reactions
Sponsors Eli Lilly and Company

Most Recent Events

11 Apr 2015 Status changed from recruiting to active, no longer recruiting, as reported in United Kingdom Clinical Research Network record.
13 Apr 2013 Status changed from active, no longer recruiting to recruiting as reported in United Kingdom Clinical Research Network record.
04 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported in United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com